SemperVirens Venture Capital — Research Report
Investment Thesis
SemperVirens Venture Capital is an ecosystem-driven, early-stage venture firm founded in 2018 by Greg Golub and Robby Peters. The firm backs category-defining B2B startups transforming the world's most complex markets — specifically the intersection of health, wealth, and work. Their core belief is that venture capital should act as an operating partner, not just a capital provider: "the best VCs act like operators and need to earn a spot on the cap table."
SemperVirens differentiates through its proprietary SemperSystem™, a structured network of 200+ Fortune 500 advisors, operators, and buyers from companies including Paychex, ADP, Cigna, MetLife, and Unum. This network functions as a GTM acceleration engine for portfolio companies, facilitating introductions to enterprise decision-makers, commercial partnerships, and customer pilots — often in regulated industries where founder networks fall short. Since inception, the firm has facilitated $500M+ in revenue opportunities and $100M+ in closed revenue for portfolio companies.
Sector Focus
SemperVirens invests across three primary verticals:
-
Healthcare Technology — Digital health, virtual care, AI-enabled clinical workflows, maternal health, mental health, and women's health. The firm targets companies selling into employer healthcare stacks and large health systems. Key portfolio companies include Spring Health (mental health, unicorn), Midi Health (women's midlife care), Pelago (substance use virtual care), Sully AI (clinical AI), Brightline (pediatric behavioral health), OneImaging (radiology imaging), Delfina (maternal intelligence), and Stepful (healthcare workforce training).
-
Workforce / HR Technology — Talent acquisition, employee benefits administration, upskilling, and AI-powered workforce tools. The firm targets companies selling into HR and benefits buyers at mid-market and enterprise employers. Key portfolio companies include Multiverse (upskilling platform, unicorn), Ashby (recruiting platform), Nayya (benefits intelligence), Thatch (health benefits platform), Carrot Fertility (fertility benefits), and Summer (student loan benefits).
-
Financial Services / Fintech — Employee financial wellness, retirement, and insurance-adjacent fintech targeting employer channels. Key portfolio companies include Human Interest (SMB retirement plans), Remote (global employment), and Rightway Healthcare.
Stage Focus
SemperVirens primarily invests at Seed and Series A, with selective follow-on through growth stage via its Growth Opportunity Fund II. Core Fund III ($141M, closed March 2025) targets early-stage investments; Growth Opportunity Fund II ($36M, closed simultaneously) funds growth-stage follow-ons in top performers. The firm has made investments across Seed, Series A, and some Series B rounds.
Check Size
Initial check sizes range from $500K to $5M. Based on reported portfolio data:
- Seed: Average round size $6.87–8M (SemperVirens likely writes $500K–$2M)
- Series A: Average round size $17–18M (SemperVirens likely writes $1M–$5M)
- Growth Opportunity Fund follow-ons add capital to top performers at Series B and beyond
Lead Tendency
SemperVirens frequently leads or co-leads early-stage rounds, particularly at Seed and early Series A. Their SemperSystem network and active operator posture mean they often drive the round structure and syndicate. They also participate as value-add follow-on investors.
Recent Activity
SemperVirens closed $177M across two new funds in March 2025 (Core Fund III: $141M, Growth Opportunity Fund II: $36M) and is actively deploying. Recent investments include:
- December 2025: Midi Health (women's healthcare)
- October 2025: OneImaging (Series A, radiology imaging)
- 2025: Sully AI, Nayya, Stepful, Thatch
- 2024: 4 investments reported
December 2025 also saw key promotions: Colin Tobias elevated to General Partner, Raquel Scott promoted to Principal, reflecting the firm's deepening focus on AI-workforce and AI-health intersections.
Portfolio Highlights
The firm has deployed capital into 70+ companies, with 2 unicorns (Multiverse, Spring Health) and 9 unicorns cited in some sources. Notable exits and milestones:
- Spring Health: Valued at $3.3B+, the leading workplace mental health solution
- Multiverse: UK-based upskilling platform, unicorn-valued
- Remote: Global employment platform, large-scale exit/growth
- Pelago: Raised $58M Series C (substance use virtual care)
- Human Interest: Leading SMB retirement platform
- Ashby: Top-tier ATS for high-growth companies
Team
- Greg Golub, Co-Founder & Managing Partner — Serial entrepreneur and operator, focused on enterprise GTM and workforce technology. LinkedIn: linkedin.com/in/greggolub
- Robby Peters, Co-Founder & Managing Partner — Experienced venture investor with deep operator background. LinkedIn: linkedin.com/in/robby-peters-80b8678
- Allison Baum Gates, General Partner — Former general partner at 500 Startups, author, and thought leader on workforce and inclusion. LinkedIn: linkedin.com/in/allisonbaumgates
- Colin Tobias, General Partner (promoted December 2025) — Focused on AI-enabled workforce and health companies
- Caribou Honig, Partner Emeritus — Co-founder of QED Investors, domain expertise in fintech and insurtech
- Raquel Scott, Principal (promoted December 2025) — Focus on AI, health tech, and workforce
Support team includes Anisha Kalyani (Head of Platform), Simran Arora (Director of Finance), Anna Caruso (Director of Investor Relations), and Samara Jaffe (Strategic Advisor & Head of HR).
Decision Process
SemperVirens operates with a partnership model. Investment decisions involve the managing partners and general partners collaboratively. The firm's SemperVirens Accelerator program also gives them deal flow and a structured evaluation framework for early companies.
Founder Preferences
SemperVirens backs founders building AI-enabled B2B companies in healthcare, workforce, and fintech — particularly those targeting large employer and enterprise buyers in regulated industries. They have a strong preference for founders who can leverage the SemperSystem network to accelerate GTM and who are willing to engage with the firm's operator support model. The firm emphasizes ecosystem fit, not just product-market fit.
Geographic Focus
Primarily US-based companies (San Francisco Bay Area, NYC, and national remote-first companies). Some investments in UK (Multiverse). The firm is headquartered in San Mateo, CA.
Anti-Thesis
SemperVirens explicitly avoids consumer-facing plays, hardware, deep biotech (pre-clinical), and companies without a clear B2B/employer-channel GTM. They focus on complex regulated markets where network access and operator support create genuine differentiation.